| 期刊論文1. | Skillington, G. Lee、Solovy, Eric M.(2003)。The Protection of Test and Other Data Required by Article 39.3 of the TRIPs Agreement。Nw. J. Int'l L. & Bus.,24,51。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 2. | Junod, Valerie(2004)。Drug Marketing Exclusivity under United States and European Union Law。Food and Drug Law Journal,59,479。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | Halperin, Robert M.(1979)。FDA Disclosure of Safety and Effectiveness Data: A Legal and Policy Analysis。DUKE L.J,11,302-310。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 4. | Pirt, Nancy E.(1987)。Regulation of the Export of Pharmaceuticals to Developing Countries。DUQ. L. REV.,25,255。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 5. | Wax, Paul M.(1995)。Elixirs, diluents, and the Passage of the 1938 Federal Food,Drug and Cosmetic Act。J ANN INTERN,122(6),456-461。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 6. | Shuren, Jeffrey E.(2001)。Essay: The Modem Regulatory Administrative State: A Response to Changing Circumstances。Harv. J. on Legis,38,291+299-301。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 7. | Merrill, Richard A.(1996)。The Architecture of Government Regulation of Medical Products。Va. L. Rev.,82,1753+1761-1766。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 8. | Weiswasser, Elizabeth Stotland、Danzis, Scott D.(2003)。The Hatch-Waxman Act: History, Structure, and Legacy。Antitrust Law Journal,71(2),585-608。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 9. | Correa, Carlos Maria(2002)。Unfair Competition under the TRIPS Agreement: Protection of Data Submitted for or the Registration of Pharmaceuticals。Chi. J. Int'l L.,3,69+73。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 10. | Fellmeth, Aaron Xavier(2004)。Secrecy, Monopoly, and Access to Pharmaceuticals in International Trade Law: Protection of Marketing Approval Data under TRIPS Agreement。Harv. Int'l LJ.,45,453-454。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 11. | Proffe, Pedro、Spennemann, Christoph(2006)。The Impact of FTAs on Public Health Policies and TRIPS Flexibilities。Int. J. Intellectual Property Management,1,75+84。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 12. | Stout, Maria Victira(2008)。Crossing the TRIPs Nondiscrimination Line: How CAFTA Pharmaceutical Patent Pm vision Violate TRIPS Article 27.1。B.U.J. Sci. & Tech, L.,14,177+195-196。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 13. | Rossi, F.。Free trade agreements and TRIPS-plus measures。lint. J. Intellectual Property Management,1(1/2)。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 14. | Cimboli, Brian(2007)。The Impact of Regional Trade Areas on International Intellectual Property Rights。IDEA,48,53+56。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 圖書1. | Watal, Jayashree(2001)。Intellectual Property Rights in the WTO and Developing Countries。Kluwer。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 2. | Nair, Manish Singh(20070915)。India: Ministries Say Yes To Data Protection。Lex Orbis。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | Abbott, Frederick M.(2006)。Intellectual Property Provisions of Bilateral and Regional Trade Agreements in Light of U.S. Federal Law。International Center for Trade and Sustainable Development。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 其他1. | WIPO。Intellectual Property and Genetic Resources, Traditional Knowledge, and Folklore,http://www.wipo.int/about-ip/en/studies/publications/genetic_resources.htm。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 圖書論文1. | Reichman, Jerome H.(2006)。The International Legal Status of Undisclosed Clinical Trial Data: From Private to Public Goods?。Negotiating Health: Intellectual Property and Access to Medicines。UK:Earthscan。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 2. | Pugatch, Meir Perez(2006)。Intellectual Property, Data Exclusivity, Innovation and Market Access。Negotiating Health: Intellectual Property and Access to Medicines。UK:Earthscan。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | Praga, Cesar(2001)。Intellectual Property。Toward Free Trade in the America: Free Trade Agreement。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | |